Condition: Netherton Syndrome · Sponsor: Quoin Pharmaceuticals
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
This description comes directly from the study's public registry record.
TI Clinical Research · 858-571-1800 · clinicalresearch@therapeuticsinc.com
Oleg G Khatsenko · 858-571-1800 · okhatsenko@therapeuticsinc.com
Always discuss trial participation with your own doctor first.
| Site #1 | San Diego, California, United States | Recruiting |
| Site #4 | Indianapolis, Indiana, United States | Recruiting |
| Site #5 | Quincy, Massachusetts, United States | Recruiting |
| Site #2 | San Antonio, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05789056